Skip to main content

How We Do It®: Pathology Considerations for Diagnosis and Therapeutic Decision Making in Hematologic Malignancies


Faculty: 
Ahmet Dogan, MD, PhD, Naval G. Daver, MD, Irene Ghobrial, MD, Susan O’Brien, MD

CME / ABIM MOC Released: 07/30/2021
Valid for credit through: 07/30/2022


Target Audience and Goal StatementThis educational program is directed toward pathologists and medical oncologists who diagnose or treat patients with hematologic malignancies. Nurses, nurse practitioners, physician assistants, and other health care professionals involved in the treatment and management of hematologic malignancies will also be invited to participate in the activity.

Clinical Cases and Conversations TM, one of PER®’s signature educational formats, is a video-based program in which a panel of distinguished experts use clinical cases to provide clinical practice perspectives and engage in discussions on a particular clinical topic. In this activity, 4 key thought leaders will first provide an overview of the current best practice and emerging strategies for diagnostic and prognostic testing in hematologic malignancies. Then, each of the expert faculty will present cases and supporting data that illustrate the incorporation of molecular testing in the diagnosis and treatment planning in acute myeloid leukemia, chronic lymphocytic leukemia, and multiple myeloma.

Acknowledgement of Commercial Support This activity is supported by an educational grant from AbbVie, Inc.

Learning Objective
Upon completion of this activity, participants will:
  • Outline guideline-based recommendations for molecular testing in hematologic malignancies
  • Identify current and emerging biomarkers that can facilitate treatment planning in hematologic malignancies
  • Evaluate clinical trial evidence in the context of how hematologic testing strategies can be utilized to optimize treatment outcomes in the setting of hematologic malignancies
  • Integrate testing approaches to stratify risk, individualize treatment, and monitor treatment response in patients with hematologic malignancies

Continuing Medical Education

For Physicians
  • Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  • Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.